Cancer Research CR Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Niho, N.
Right arrow Articles by Wakabayashi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niho, N.
Right arrow Articles by Wakabayashi, K.
[Cancer Research 63, 6090-6095, September 15, 2003]
© 2003 American Association for Cancer Research

Epidemiology and Prevention

Concomitant Suppression of Hyperlipidemia and Intestinal Polyp Formation in Apc-deficient Mice by Peroxisome Proliferator-activated Receptor Ligands1

Naoko Niho2, Mami Takahashi, Tomohiro Kitamura, Yutaka Shoji, Masaki Itoh, Tetsuo Noda, Takashi Sugimura and Keiji Wakabayashi

Cancer Prevention Division, National Cancer Center Research Institute, Tokyo 104-0045 [N. N., M. T., T. K., Y. S., T. S., K. W.]; Cell Biology Department, Cancer Institute, Tokyo 170-8455 [M. I., T. N.]; Oncology Department, Jikei University School of Medicine, Tokyo 105-8461 [M. I.]; and The Core Research for Evolutional Science and Technology Program, Japan Science and Technology Corporation, Kawaguchi 332-0012 [T. N.], Japan

Epidemiological studies have shown a positive association of colon cancer with hyperlipidemia. Furthermore, signaling generated by peroxisome proliferator-activated receptor (PPAR) {alpha} and {gamma} ligands, suggested to be candidate tumor preventive agents, has been shown to lower serum triglyceride levels. In the present study, we assessed hyperlipidemia in Apc-deficient mice, model animals for human familial adenomatous polyposis, and examined the effects of pioglitazone and bezafibrate, respectively, PPAR{gamma} and PPAR{alpha} agonists, on both hyperlipidemia and intestinal polyposis. Serum lipid levels in Apc1309 mice and Min mice from 6 to 15 weeks of age were measured. Although serum levels of triglyceride and cholesterol were low in both Apc1309 and wild-type mice at 6 weeks, triglycerides were elevated 10-fold in Apc1309 mice by the age of 12 weeks but not in their wild-type counterparts. Cholesterol was also increased significantly, and marked centrilobular-restricted steatosis was observed in the livers of aged Apc1309 mice. Similar findings were observed for Min mice at 15 weeks of age. Moreover, lipoprotein lipase mRNA levels in the liver and small intestine of Apc1309 and Min mice were demonstrated to be lower than those in wild-type mice. Treatment of Apc1309 mice with 100 and 200 ppm pioglitazone or bezafibrate for 6 weeks from 6 weeks of age caused dose-dependent reduction in serum triglycerides and cholesterol, along with reduction in the numbers of intestinal polyps to 67% of the control value. The present study clearly demonstrated a hyperlipidemic state in Apc gene-deficient mice and a potential of PPAR{alpha} and PPAR{gamma} ligands to suppress both hyperlipidemia and polyp formation. Hyperlipidemia in these mice may thus be associated with their intestinal lesion development.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
T. Matsunaka, S. Miyamoto, K. Shitara, A. Ochiai, and T. Chiba
Ligand-Specific Antibodies to Insulin-Like Growth Factors Suppress Intestinal Polyp Formation in Apc+/- Mice
Mol. Cancer Ther., February 1, 2010; 9(2): 419 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Yamaguchi, M. Cekanova, M. F. McEntee, J.-H. Yoon, S. M. Fischer, I. B. Renes, I. Van Seuningen, and S. J. Baek
Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways
Mol. Cancer Ther., September 1, 2008; 7(9): 2779 - 2787.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Miyamoto, Y. Yasui, T. Tanaka, H. Ohigashi, and A. Murakami
Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice
Carcinogenesis, May 1, 2008; 29(5): 1057 - 1063.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Mutoh, N. Niho, M. Komiya, M. Takahashi, R. Ohtsubo, K. Nakatogawa, K. Ueda, T. Sugimura, and K. Wakabayashi
Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice
Carcinogenesis, April 1, 2008; 29(4): 824 - 829.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
K. N. Ealey, S. Lu, D. Lau, and M. C. Archer
Reduced susceptibility of muscle-specific insulin receptor knockout mice to colon carcinogenesis
Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G679 - G686.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Panigrahy, A. Kaipainen, S. Huang, C. E. Butterfield, C. M. Barnes, M. Fannon, A. M. Laforme, D. M. Chaponis, J. Folkman, and M. W. Kieran
PPAR{alpha} agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition
PNAS, January 22, 2008; 105(3): 985 - 990.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Sakano, M. Takahashi, M. Mutoh, N. Niho, M. Komiya, H. Sato, T. Tanaka, T. Sugimura, and K. Wakabayashi
Enhanced thyroid carcinogenicity of N-nitrosobis(2-oxopropyl)amine in Otsuka Long-Evans Tokushima Fatty rats, a model of type II diabetes mellitus
Carcinogenesis, October 1, 2007; 28(10): 2193 - 2198.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
W. Su, C. R. Bush, B. M. Necela, S. R. Calcagno, N. R. Murray, A. P. Fields, and E. A. Thompson
Differential expression, distribution, and function of PPAR-{gamma} in the proximal and distal colon
Physiol Genomics, August 20, 2007; 30(3): 342 - 353.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. R. Bush, J. M. Havens, B. M. Necela, W. Su, L. Chen, M. Yanagisawa, P. Z. Anastasiadis, R. Guerra, B. A. Luxon, and E. A. Thompson
Functional Genomic Analysis Reveals Cross-talk between Peroxisome Proliferator-activated Receptor {gamma} and Calcium Signaling in Human Colorectal Cancer Cells
J. Biol. Chem., August 10, 2007; 282(32): 23387 - 23401.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Takeuchi, M. Takahashi, K. Sakano, M. Mutoh, N. Niho, M. Yamamoto, H. Sato, T. Sugimura, and K. Wakabayashi
Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor {gamma}
Carcinogenesis, August 1, 2007; 28(8): 1692 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Pozzi, M. R. Ibanez, A. E. Gatica, S. Yang, S. Wei, S. Mei, J. R. Falck, and J. H. Capdevila
Peroxisomal Proliferator-activated Receptor-{alpha}-dependent Inhibition of Endothelial Cell Proliferation and Tumorigenesis
J. Biol. Chem., June 15, 2007; 282(24): 17685 - 17695.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Govindarajan, L. Ratnasinghe, D. L. Simmons, E. R. Siegel, M. V. Midathada, L. Kim, P. J. Kim, R. J. Owens, and N. P. Lang
Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes
J. Clin. Oncol., April 20, 2007; 25(12): 1476 - 1481.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Chintharlapalli, S. Papineni, and S. Safe
1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPAR{gamma}-dependent and PPAR{gamma}-independent pathways
Mol. Cancer Ther., May 1, 2006; 5(5): 1362 - 1370.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Mutoh, T. Akasu, M. Takahashi, N. Niho, T. Yoshida, T. Sugimura, and K. Wakabayashi
Possible Involvement of Hyperlipidemia in Increasing Risk of Colorectal Tumor Development in Human Familial Adenomatous Polyposis
Jpn. J. Clin. Oncol., March 1, 2006; 36(3): 166 - 171.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. S. Kota, C. V. Ramana, F. A. Tenorio, R. I. Enelow, and J. C. Rutledge
Differential Effects of Lipoprotein Lipase on Tumor Necrosis Factor-{alpha} and Interferon-{gamma}-mediated Gene Expression in Human Endothelial Cells
J. Biol. Chem., September 2, 2005; 280(35): 31076 - 31084.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Niho, M. Mutoh, M. Takahashi, K. Tsutsumi, T. Sugimura, and K. Wakabayashi
Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice
PNAS, February 22, 2005; 102(8): 2970 - 2974.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell
Nutritional modulation of the cell cycle and breast cancer
Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. Hulit, C. Wang, Z. Li, C. Albanese, M. Rao, D. Di Vizio, S. Shah, S. W. Byers, R. Mahmood, L. H. Augenlicht, et al.
Cyclin D1 Genetic Heterozygosity Regulates Colonic Epithelial Cell Differentiation and Tumor Number in ApcMin Mice
Mol. Cell. Biol., September 1, 2004; 24(17): 7598 - 7611.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Chintharlapalli, R. Smith III, I. Samudio, W. Zhang, and S. Safe
1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes Induce Peroxisome Proliferator-Activated Receptor {gamma}-Mediated Growth Inhibition, Transactivation, and Differentiation Markers in Colon Cancer Cells
Cancer Res., September 1, 2004; 64(17): 5994 - 6001.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. H. Itzkowitz and X. Yio
Inflammation and Cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
Am J Physiol Gastrointest Liver Physiol, July 1, 2004; 287(1): G7 - G17.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.